Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer
PHASE3Not yet recruitingINTERVENTIONAL
Enrollment
95
Participants
Timeline
Start Date
December 1, 2024
Primary Completion Date
January 1, 2027
Study Completion Date
January 1, 2027
Conditions
Women With Breast Cancer
Interventions
DRUG
Prasterone (DHEA)
Prasterone 6.5 mg vaginal tablets
Trial Locations (1)
20141
European Institute of Oncology, Milan
All Listed Sponsors
lead
European Institute of Oncology
OTHER
NCT06611514 - Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer | Biotech Hunter | Biotech Hunter